The CGA-IGC 2024 annual meeting was a defining moment for Lynsight as we introduced our rebrand to an engaged community of professionals dedicated to hereditary cancer research and care. We’re so grateful for the opportunity to share our vision for the future of Lynch syndrome diagnostics and to connect with others who share our commitment to improving patient outcomes.
New Name, Same Dedication
Lynch syndrome is the most common cause of hereditary gastrointestinal cancers, impacting approximately 1 in 279 individuals, yet it remains underdiagnosed. At Lynsight, we’re committed to changing that reality.
For over a decade, our team has worked tirelessly to develop DiagMMR, an innovative assay that provides clearer, more accurate insights into Lynch syndrome. Our rebrand reflects our evolution and strengthens our mission: to empower families and healthcare professionals to make better-informed decisions for cancer prevention.
Building Connections and Advancing Awareness
Building Connections and Advancing AwarenessThroughout CGA-IGC, Lynsight’s team engaged with healthcare providers, researchers, and advocates, sparking meaningful conversations about the importance of early and accurate Lynch syndrome detection. These interactions underscore the pressing need for continued innovation in the field to improve diagnostic rates of Lynch syndrome and enable truly personalized preventative care.
“Many of our conversations revolved around the opportunity to measure the level of mismatch deficiency in Lynch syndrome patients. In theory, that might enable us to assess personal risk and our technology has the potential to provide that type of insight. While we are not there yet, it’s always incredibly valuable to hear feedback and needs from our potential customers of where their biggest pain points are, and how we might possibly help to relieve those in the near future.”
– Philippe Arnez, Head of Culture & Communication
A Celebration of Progress
The warm reception to our new identity was a powerful reminder of the impact we can make when we come together as a community. Attendees expressed excitement about Lynsight’s direction and our contributions to advancing Lynch syndrome awareness and care. CGA-IGC was not only a celebration of our evolution but also a testament to the shared dedication of everyone working toward a better future for patients and families.
“The event made a strong impression, with participants actively engaging in discussions and sharing their insights. The collective dedication to advancing research and improving patient outcomes was evident throughout every aspect of the event, reinforcing the inspiration that drives our team”
– Minttu Kansikas, Chief Scientific Officer
Looking to the Future
As we move forward, we remain inspired by the energy and enthusiasm of the CGA-IGC community. Lynsight is committed to fostering partnerships and driving progress in hereditary cancer diagnostics, and we’re excited to share what’s ahead.
Thank you to everyone who visited us at the CGA-IGC show—together, we’re shaping a brighter future for hereditary cancer diagnostics.
